Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin for S. aureus infections in opioid users
NCT03761953Phase 4Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oritavancin in Staphylococcus aureus bacteremia (SAB) and infective endocarditis (IE), sponsored by University of Pennsylvania. Primary endpoints: Frequency of grade 3 or 4 systemic adverse events at 6 weeks and Frequency of relapse of infection at 6 weeks. Planned start Jul 2019; status: withdrawn.
02
Drugs
oritavancin
03
Conditions
Staphylococcus aureus bacteremia (SAB)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT03761953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761953.